Found: 134
Select item for more details and to access through your institution.
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.
- Published in:
- 2017
- By:
- Publication type:
- journal article
A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human...
- Published in:
- JNCI: Journal of the National Cancer Institute, 1994, v. 86, n. 1, p. 30, doi. 10.1093/jnci/86.1.30
- By:
- Publication type:
- Article
Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere.
- Published in:
- 1993
- By:
- Publication type:
- Case Study
Activity of Topotecan, a New Topoisomerase I Inhibitor, Against Human Tumor Colony-Forming Units In Vitro.
- Published in:
- JNCI: Journal of the National Cancer Institute, 1992, v. 84, n. 23, p. 1816, doi. 10.1093/jnci/84.23.1816
- By:
- Publication type:
- Article
A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).
- Published in:
- 2022
- By:
- Publication type:
- journal article
Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Trastuzumab Emtansine (T-DM1): A Novel Agent for Targeting HER2+ Breast Cancer.
- Published in:
- Clinical Breast Cancer, 2011, v. 11, n. 5, p. 275, doi. 10.1016/j.clbc.2011.03.018
- By:
- Publication type:
- Article
Phase II Study of Neoadjuvant Weekly nab- Paclitaxel and Carboplatin, With Bevacizumab and Trastuzumab, As Treatment For Women With Locally Advanced HER2+ Breast Cancer.
- Published in:
- Clinical Breast Cancer, 2011, v. 11, n. 5, p. 297, doi. 10.1016/j.clbc.2011.04.002
- By:
- Publication type:
- Article
Hormonal Therapy Plus Bevacizumab in Postmenopausal Patients Who Have Hormone Receptor-Positive Metastatic Breast Cancer: A Phase II Trial of the Sarah Cannon Oncology Research Consortium.
- Published in:
- Clinical Breast Cancer, 2011, v. 11, n. 3, p. 146, doi. 10.1016/j.clbc.2011.03.010
- By:
- Publication type:
- Article
A Phase II Trial of Dose-Dense Neoadjuvant Gemcitabine, Epirubicin, and Albumin-Bound Paclitaxel With Pegfilgrastim in the Treatment of Patients With Locally Advanced Breast Cancer.
- Published in:
- Clinical Breast Cancer, 2010, v. 10, n. 5, p. 367, doi. 10.3816/CBC.2010.n.048
- By:
- Publication type:
- Article
Phase II Trial of Docetaxal Plus Imatinib Mesylate in the Treatment of Patients With Metastatic Breast Cancer.
- Published in:
- Clinical Breast Cancer, 2009, v. 9, n. 4, p. 237, doi. 10.3816/CBC.2009.n.040
- By:
- Publication type:
- Article
A Phase II Randomized Crossover Study of Liposomal Doxorubicin Versus Weekly Docetaxel in the First-line Treatment of Women With Metastatic Breast Cancer.
- Published in:
- Clinical Breast Cancer, 2009, v. 9, n. 4, p. 247, doi. 10.3816/CBC.2009.n.042
- By:
- Publication type:
- Article
Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With HER2-Overexpressing Metastatic Breast Cancer.
- Published in:
- Clinical Breast Cancer, 2009, v. 9, n. 3, p. 178, doi. 10.3816/CBC.2009.n.029
- By:
- Publication type:
- Article
Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 1, p. 107, doi. 10.1002/cpdd.575
- By:
- Publication type:
- Article
Relative Bioavailability of Pediatric Oral Solution and Tablet Formulations of Trametinib in Adult Patients With Solid Tumors.
- Published in:
- Clinical Pharmacology in Drug Development, 2015, v. 4, n. 4, p. 287, doi. 10.1002/cpdd.152
- By:
- Publication type:
- Article
Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma.
- Published in:
- Clinical Genitourinary Cancer, 2022, v. 20, n. 1, p. 35, doi. 10.1016/j.clgc.2021.10.004
- By:
- Publication type:
- Article
A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2024, v. 204, n. 1, p. 123, doi. 10.1007/s10549-023-07167-9
- By:
- Publication type:
- Article
A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2024, v. 203, n. 3, p. 123, doi. 10.1007/s10549-023-07167-9
- By:
- Publication type:
- Article
Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2.
- Published in:
- Breast Cancer Research & Treatment, 2018, v. 170, n. 3, p. 535, doi. 10.1007/s10549-018-4769-z
- By:
- Publication type:
- Article
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 6, p. 1016, doi. 10.1007/s10637-018-0591-z
- By:
- Publication type:
- Article
A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 5, p. 576, doi. 10.1007/s10637-017-0459-7
- By:
- Publication type:
- Article
Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
- Published in:
- 2017
- By:
- Publication type:
- Erratum
A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 2, p. 216, doi. 10.1007/s10637-016-0327-x
- By:
- Publication type:
- Article
A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 6, p. 1187, doi. 10.1007/s10637-015-0278-7
- By:
- Publication type:
- Article
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 2, p. 463, doi. 10.1007/s10637-015-0218-6
- By:
- Publication type:
- Article
A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 187, doi. 10.1007/s10637-014-0177-3
- By:
- Publication type:
- Article
A Phase II Study of Higher Dose Weekly Topotecan in Relapsed Small-Cell Lung Cancer.
- Published in:
- Clinical Lung Cancer, 2011, v. 12, n. 3, p. 187, doi. 10.1016/j.cllc.2011.03.016
- By:
- Publication type:
- Article
Phase II Study of Cetuximab, Docetaxel, and Gemcitabine in Patients With Previously Untreated Advanced Non–Small-Cell Lung Cancer.
- Published in:
- Clinical Lung Cancer, 2010, v. 11, n. 3, p. 198, doi. 10.3816/CLC.2010.n.026
- By:
- Publication type:
- Article
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum].
- Published in:
- International Journal of Nanomedicine, 2019, v. 14, p. 5751, doi. 10.2147/IJN.S207276
- By:
- Publication type:
- Article
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.
- Published in:
- International Journal of Nanomedicine, 2015, v. 10, p. 1201, doi. 10.2147/IJN.S62911
- By:
- Publication type:
- Article
Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma.
- Published in:
- 1999
- By:
- Publication type:
- journal article
Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer.
- Published in:
- Cancer (0008543X), 1999, v. 85, n. 5, p. 1179, doi. 10.1002/(SICI)1097-0142(19990301)85:5<1179::AID-CNCR23>3.0.CO;2-I
- By:
- Publication type:
- Article
Testicular relapse in adult acute myelogenous leukemia.
- Published in:
- Cancer (0008543X), 1992, v. 70, n. 6, p. 1541, doi. 10.1002/1097-0142(19920915)70:6<1541::AID-CNCR2820700616>3.0.CO;2-6
- By:
- Publication type:
- Article
Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 135, doi. 10.1007/s10637-013-9952-9
- By:
- Publication type:
- Article
A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 87, doi. 10.1007/s10637-013-9949-4
- By:
- Publication type:
- Article
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 4, p. 891, doi. 10.1007/s10637-012-9887-6
- By:
- Publication type:
- Article
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 4, p. 927, doi. 10.1007/s10637-012-9900-0
- By:
- Publication type:
- Article
Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 363, doi. 10.1007/s10637-012-9823-9
- By:
- Publication type:
- Article
A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 3, p. 467, doi. 10.1007/s10637-009-9374-x
- By:
- Publication type:
- Article
A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer.
- Published in:
- Investigational New Drugs, 2009, v. 27, n. 1, p. 75, doi. 10.1007/s10637-008-9160-1
- By:
- Publication type:
- Article
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
- Published in:
- Breast Cancer Research & Treatment, 2018, v. 167, n. 3, p. 659, doi. 10.1007/s10549-017-4523-y
- By:
- Publication type:
- Article
Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute.
- Published in:
- Breast Cancer Research & Treatment, 2015, v. 154, n. 1, p. 89, doi. 10.1007/s10549-015-3599-5
- By:
- Publication type:
- Article
A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score.
- Published in:
- Breast Cancer Research & Treatment, 2015, v. 154, n. 2, p. 299, doi. 10.1007/s10549-015-3613-y
- By:
- Publication type:
- Article